Evergreen Private Wealth LLC lifted its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 10.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 32,931 shares of the company's stock after buying an additional 3,184 shares during the period. Zoetis comprises approximately 2.2% of Evergreen Private Wealth LLC's holdings, making the stock its 20th largest holding. Evergreen Private Wealth LLC's holdings in Zoetis were worth $5,136,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Nova Wealth Management Inc. acquired a new position in shares of Zoetis in the 1st quarter worth approximately $25,000. 1248 Management LLC bought a new stake in Zoetis during the 1st quarter worth approximately $27,000. Saudi Central Bank bought a new stake in Zoetis during the 1st quarter worth approximately $29,000. Cornerstone Planning Group LLC grew its position in Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after acquiring an additional 88 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. grew its position in Zoetis by 87.6% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after acquiring an additional 120 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.
Zoetis Stock Down 0.5%
Shares of ZTS opened at $141.03 on Friday. The firm has a market capitalization of $62.50 billion, a price-to-earnings ratio of 24.27, a PEG ratio of 2.27 and a beta of 0.89. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The business's fifty day moving average price is $150.45 and its two-hundred day moving average price is $155.86. Zoetis Inc. has a 52 week low of $139.34 and a 52 week high of $197.51.
Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same period last year, the company earned $1.56 EPS. The firm's revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.
Analyst Ratings Changes
A number of equities research analysts recently commented on the company. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and decreased their price target for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Argus restated a "buy" rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Piper Sandler increased their price target on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Finally, Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and decreased their price objective for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $200.88.
Get Our Latest Stock Analysis on Zoetis
Zoetis Profile
(
Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Further Reading
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
